natgillin/translations-raw huggingface dataset:
INTELENCE (200 mg b.i.d.), evaluated in combination with other antiretroviral medicinal products in a study of 15 pregnant women during the second and third trimesters of pregnancy and postpartum, demonstrated that exposure to total etravirine was generally higher during pregnancy compared with postpartum, and less so for unbound etravirine exposure (see section 5.2).
Ocena zdravila INTELENCE (200 mg, b.i.d.) v kombinaciji z drugimi protiretrovirusnimi zdravili v študiji pri 15 nosečnicah med drugim in tretjim trimesečjem nosečnosti in v obdobju po porodu je pokazala, da je bila celokupna izpostavljenost etravirinu na splošno večja med nosečnostjo kot po porodu, razlika v izpostavljenosti pri nevezanem etravirinu pa je bila manjša (glejte poglavje 5.2).
INTELENCE (see
zdravila INTELENCE ni
INTELENCE and
INTELENCE z
INTELENCE and
Zdravilo INTELENCE in
INTELENCE and raltegravir
Zdravilo INTELENCE in
INTELENCE and telaprevir
telaprevir se lahko
INTELENCE can be
Zdravilo INTELENCE lahko
INTELENCE can be
Zdravilo INTELENCE se
INTELENCE can be used
INTELENCE lahko uporabljate brez prilagoditve
Intelence does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Intelence ne zdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
Intelence has also been studied in one main study involving 101 children aged between six and 17 years old who were infected with HIV and were already taking anti-HIV medicines.
Zdravilo Intelence so proučevali tudi v eni glavni študiji, v katero je bil vključen 101 otrok v starosti od šest do 17 let.
INTELENCE has no or negligible influence on the ability to drive and use machines.
Zdravilo INTELENCE nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
INTELENCE has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and is therefore not recommended (see sections 4.2 and 4.4).
Pri bolnikih s hudo jetrno okvaro (razred C po klasifikaciji Child-Pugh) zdravila INTELENCE niso proučevali, zato uporaba zdravila pri njih ni priporočljiva (glejte poglavji 4.2 in 4.4).
Intelence is a medicine that contains the active substance etravirine.
Intelence je zdravilo, ki vsebuje zdravilno učinkovino etravirin.
INTELENCE is expected to increase nelfinavir plasma concentrations.
Pričakovati je, da zdravilo INTELENCE zviša plazemske koncentracije nelfinavirja.
INTELENCE is expected to increase plasma concentrations of warfarin.
Pričakovati je, da zdravilo INTELENCE zviša plazemsko koncentracijo varfarina.
Intelence is only used in patients who have been treated for their HIV infection before.
Zdravilo se uporablja le pri bolnikih, ki so se že zdravili zaradi okužbe z virusom HIV.
Intelence is used to treat adults and children from six years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Intelence se uporablja za zdravljenje odraslih in otrok, starejših od šest let, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Intelence must be used together with other anti-HIV medicines that include a ‘boosted protease inhibitor’.
Uporabljati se mora skupaj z drugimi zdravili za zdravljenje okužbe z virusom HIV, ki morajo vključevati „okrepljeni zaviralec proteaze“.
INTELENCE should be used in combination with a boosted protease inhibitor (PI).
Zdravilo INTELENCE je treba uporabljati skupaj z okrepljenimi zaviralci proteaze (PI).
INTELENCE should only be used with dolutegravir when co-administered with
lahko uporablja z dolutegravirjem le sočasno s kombinacijami
INTELENCE should optimally be combined with other antiretrovirals that exhibit activity against the patient’s virus (see section 5.1).
Optimalno je, da uporabo zdravila INTELENCE kombinirate z drugimi protiretrovirusnimi zdravili, ki učinkujejo proti bolnikovemu virusu (glejte poglavje 5.1).
INTELENCE tablet(s) should be taken orally, following a meal (see section 5.2).
Tableto zdravila INTELENCE je treba vzeti peroralno, po obroku (glejte poglavje 5.2).
INTELENCE tablets should be stored in the original bottle.
Zdravilo INTELENCE tablete shranjujte v originalni plastenki.
Intelence was more effective than placebo at reducing viral load in adults.
Zdravilo Intelence je bilo pri zmanjševanju virusne obremenitve pri odraslih učinkovitejše od placeba.
Intelence was originally given ‘conditional approval’ because there was more evidence to come about the medicine, in particular regarding its use in combination with protease inhibitors other than darunavir.
Zdravilo Intelence je prvotno pridobilo „pogojno dovolenje za promet“, ker je bilo pričakovati dodatne dokaze o njem, zlasti glede njegove uporabe v kombinaciji z zaviralci proteaze, razen z darunavirjem.
INTELENCE with a boosted
INTELENCE z okrepljenim
Intense lack of energy
močno pomanjkanje energije
Intensification of therapy with insulin, a component of Xultophy, with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long- term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Intenziviranje zdravljenja z insulinom, ene od sestavin zdravila Xultophy, s hitrim izboljšanjem urejenosti glikemije, lahko spremlja prehodno poslabšanje diabetične retinopatije, medtem ko dolgoročno izboljšanje urejenosti glikemije zmanjša tveganje za napredovanje diabetične retinopatije.
Intensified control in the treatment of pregnant women with diabetes is therefore recommended throughout pregnancy and when contemplating pregnancy.
Zato je pri ženskah z diabetesom med nosecnostjo in kadar želijo zanositi priporocljivo intenzivnejše nadziranje.
intensify your reaction to the cancer medicines fluorouracil and vincristine. cause an unwanted drop in blood pressure when you are treated with medicines called ACE inhibitors, which are used to treat high blood pressure and other conditions. increase drowsiness when used at the same time as alcohol or medicines that can cause drowsiness.
okrepi vašo reakcijo na zdravili proti raku fluorouracilu in vinkristinu, povzroči neželen padec krvnega tlaka, če se zdravite z zdravili, imenovanimi zaviralci ACE, ki se uporabljajo za zdravljenje visokega krvnega tlaka in drugih bolezni. poveča dremavost, če se uporablja sočasno z alkoholom ali zdravili, ki lahko povzročijo dremavost.
Intensity of the adverse reactions is graded according to NCI CTC version 3.0 (grade ≥3 = G≥3).
Izrazitost neželenih učinkov je ocenjena po NCI CTC verzija 3.0 (stopnja ≥ 3 = S≥3).
intensive care unit (ICU) or similar
intenzivne terapije ali v podobni
Intent to Treat
Namen zdraviti
Intent to Treat
Namera zdravljenja
Intent to Treat Populationb
Populacija bolnikov, ki naj bi jo zdravili (ITT)b
Intent to Treat Populationb
Populacija bolnikov, ki naj bi jo zdravili (TTP)b
Intent-to-treat
ITT populacija
Intent-to-treat
Namen zdraviti
Intent-to-treat
Vključeni bolniki ("intent-to- treat")
Intent-to-treat (ITT) analysis includes patients who received open-label vandetanib before progression according to the central read.
Analiza »z- namenom-zdravljenja« (ITT – "Intent to treat") vključuje bolnike, ki so odprto ("open-label") prejemali vandetanib pred napredovanjem v skladu s centralnim odčitkom.
Intent-to-treat (ITT) analysis includes patients who received open-label vandetanib before progression according to the central read.
Analiza »z- namenom-zdravljenja« (ITT – "Intent to treat")) vključuje bolnike, ki so odprto ("open-label") prejemali vandetanib pred napredovanjem v skladu s centralnim odčitkom.
Intent-to-Treat Analysis Set+
Analiza za preiskovance, ki so jih nameravali zdraviti+
Intent-To-Treat Population
Populacija z namenom zdravljenja
Intent-to-treat population using last observation in study prior to glycaemic rescue therapy. p < 0.001 compared to placebo.
populacija z namenom zdravljenja (intention-to-treat) z uporabo zadnje meritve v študiji pred prejemom nujnih zdravil v primeru hipoglikemije p < 0,001 v primerjavi s placebom
Intent-to-treat population using last observation in study prior to glycaemic rescue therapy. p < 0.001 compared to placebo.
populacija, ki so jo nameravali zdraviti (intention-to-treat) z uporabo zadnje meritve v študiji pred prejemom nujnih zdravil v primeru hipoglikemije p < 0,001 v primerjavi s placebom
Intent-to-treat population using last observation in study. p < 0.001 compared to placebo.
populacija, ki so jo nameravali zdraviti (intention-to-treat) z uporabo zadnje meritve v študiji p < 0,001 v primerjavi s placebom
Intentional drug misuse Medication error
padec namerna zloraba zdravil uporaba napačnega zdravila
Inter and intra patient variabilities in plasma exposure were lower than 20% and 10%, respectively.
Odstopanja pri izpostavljenosti v plazmi so bila med bolniki manjša od 20 %, pri posameznem bolniku pa manjša od 10 %.
Inter individual variation in total body clearance was approximately 50%.
Interindividualno variiranje celotnega telesnega očistka je bilo približno 50 %.
Inter individual variation in total body clearance was approximately 50%.
Odklon celotnega telesnega očistka med posamezniki je bil pribliţno 50 %.
Inter individual variation in total body clearance was approximately 50%.
Odklon celotnega telesnega očistka med posamezniki je bil približno 50 %.
Inter-conversion between caffeine and theophylline has been reported in preterm newborn infants; caffeine levels are approximately 25% of theophylline levels after theophylline administration and approximately 3-8% of caffeine administered would be expected to convert to theophylline.
Pri nedonošenih novorojenčkih so poročali o interkonverziji med kofeinom in teofilinom; ravni kofeina so približno 25 % ravni teofilina po dajanju teofilina in pričakuje se, da se približno 3-8 % kofeina spremeni v teofilin.
Inter-ethnic differences
Medetnične razlike
Inter-ethnic differences
Razlike med etničnimi skupinami
Inter-individual variability (CV) of riociguat exposure (AUC) across all doses is approximately 60%.
Interindividualna variabilnost (CV) izpostavljenosti riociguatu (AUC) je za vse odmerke približno 60 %.
Inter-rater agreement using Fleiss’ kappa values ranged from 0.75 to 0.85.
Ujemanje med ocenjevanji, določeno z uporabo Fleissovih vrednosti kappa, je bilo v razponu med 0,75 in 0,85.
Inter-subject pharmacokinetic variability for pregabalin is low (<20%).
Razlike v farmakokinetiki pregabalina od posameznika do posameznika so majhne (< 20%).
Inter-subject variability is high with a CV% of about 50% for CL and 60% for Vss.
Variabilnost med preiskovanci je velika: KV (koeficient variabilnosti)za očistek znaša približno 50 % in KV za Vss približno 60 %.
Interacting substances
Zdravila, ki lahko privedejo do interakcij
Interaction
CYP2C9]
Interaction
glipizid, gliburid)
Interaction
in placebo.
Interaction
Karbamazepin
Interaction
Medsebojnega delovanja z
Interaction
Medsebojno delovanje je možno.
Interaction
Medsebojno delovanje z drugimi
Interaction
podaljšane sedacije.
Interaction
zmanjšale.
Interaction
↑ Daklatasvir
Interaction (mechanism, if known)
Medsebojno delovanje ni raziskano.
Interaction (postulated mechanism of action, if known)
INHIBITORJI PROTONSKE ČRPALKE
Interaction affecting the use of ONIVYDE
Interakcije, ki vplivajo na uporabo zdravila ONIVYDE
Interaction geometric mean change (%)
Interakcija Geometrijsko povprečje spremembe (%)
Interaction has not been studied.
Interakcija ni raziskana.
Interaction not studied
indinavir:
Interaction not studied
Interakcij niso preučevali.
Interaction not studied
Interakcije niso
Interaction not studied
Interakcije niso preučevali.
Interaction not studied
Medsebojnega delovanja niso preučevali.
Interaction not studied
Medsebojno delovanje ni
Interaction not studied
Študij medsebojnega delovanja zdravil ni.
Interaction not studied for this fixed dose combination tablet.
Interakcij s to kombinacijo učinkovin
Interaction not studied with
Interakcij z elvitegravirjem niso
Interaction not studied with any components of Eviplera.
Interakcij z drugimi sestavinami zdravila Eviplera niso preučevali.
Interaction not studied with any of the components of Genvoya.
Interakcij niso preučili z nobeno od učinkovin zdravila Genvoya.
Interaction not studied with any of the components of Stribild.
Interakcij niso preučevali za nobeno od učinkovin zdravila Stribild.
Interaction not studied with tenofovir alafenamide.
Interakcij z alafenamidtenofoviratom niso preučevali.
Interaction not studied.
(mehanizem)
Interaction not studied.
ANTIKOAGULANTI
Interaction not studied.
buprenorfin:
Interaction not studied.
med učinkovinami niso
Interaction not studied.
na protiretrovirusnem
Interaction not studied.
ne sme uporabljati sočasno
Interaction not studied.
pravastatin/dizoproksiltenofovirijev fumarat
Interaction not studied.
telaprevir/efavirenz
Interaction not studied.
tenofovir:
Interaction not studied.
uporabe z zdravilom
Interaction not studied.
vigabatrin/efavirenz gabapentin/efavirenz
Interaction not studied.
Študij medsebojnega delovanja
Interaction not studied.
Študij medsebojnega delovanja zdravil ni.
Interaction of P-gp substrates
Medsebojno delovanje s substratom P-gp
Interaction of vemurafenib with drug transport systems
Medsebojno delovanje vemurafeniba s transportnimi sistemi zdravil
Interaction on medicinal products metabolised by CYP 2D6: beta blockers, antidepressants
Medsebojna delovanja z zdravili, ki se presnovijo s CYP 2D6: zaviralci beta, antidepresivi
Interaction on medicinal products metabolized by CYP 3A4
Medsebojna delovanja z zdravili, ki se presnovijo s CYP 3A4
Interaction on metformin (OCT1 and OCT2 substrate)
Medsebojno delovanje na metformin (substrat OCT1 in OCT2)
Interaction on omeprazole (CYP 2C19 substrate)
Medsebojno delovanje na omeprazol (substrat CYP 2C19)
Interaction on theophylline (CYP 1A2 substrate)
Medsebojno delovanje s teofilinom (substratom CYP 1A2)
Interaction on warfarin and losartan (CYP 2C9 substrates)
Medsebojno delovanje z varfarinom in losartanom (substratoma CYP 2C9)
Interaction only studied with sofosbuvir
Preučevane so bile samo interakcije s sofosbuvirjem
Interaction only studied with velpatasvir
Preučevane so bile samo interakcije z velpatasvirjem.
interaction seen.
medsebojnih učinkov.
interaction should be taken into
interakcije upoštevati pri izbiri
Interaction studies conducted in healthy subjects, using mainly a single dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
Izvedene študije medsebojnega delovanja pri zdravih osebah, ki so bile v glavnem izvedene po raziskovalnem načrtu z uporabo enkratnega odmerka, ne kažejo, da bi metformin, pioglitazon, sitagliptin, glimepirid, vogliboza, hidroklorotiazid, bumetanid, valsartan ali simvastatin spremenili farmakokinetiko dapagliflozina.
Interaction studies conducted in healthy subjects, using mainly a single-dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
Študije medsebojnega delovanja pri zdravih preiskovancih, opravljene v glavnem po raziskovalnem načrtu z enim odmerkom, kažejo, da pioglitazon, sitagliptin, glimepirid, voglibos, hidroklorotiazid, bumetanid, valsartan ali simvastatin ne spremenijo farmakokinetike dapagliflozina.
Interaction studies conducted in healthy volunteers suggest that the pharmacokinetics of empagliflozin were not influenced by co-administration with metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, torasemide and hydrochlorothiazide.
Študije medsebojnega delovanja pri zdravih prostovoljcih kažejo, da sočasna uporaba metformina, glimepirida, pioglitazona, sitagliptina, linagliptina, varfarina, verapamila, ramiprila, simvastatina, torazemida in hidroklorotiazida ni vplivala na farmakokinetiko empagliflozina.
Interaction studies conducted in healthy volunteers suggest that the pharmacokinetics of empagliflozin were not influenced by co-dministration with metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, torasemide and hydrochlorothiazide.
Študije medsebojnega delovanja pri zdravih prostovoljcih kažejo, da sočasna uporaba metformina, glimepirida, pioglitazona, sitagliptina, linagliptina, varfarina, verapamila, ramiprila, simvastatina, torasemida in hidroklorotiazida ni vplivala na farmakokinetiko empagliflozina.
Interaction studies have been performed only in adults.
Študije medsebojnega delovanja so izvedli le pri odraslih.
Interaction studies have not been conducted in patients on dialysis.
Pri bolnikih, ki se zdravijo z dializo, študij medsebojnega delovanja niso izvedli.
Interaction studies have only been performed in adults
Študije medsebojnega delovanja so izvedli le pri odraslih.
Interaction studies have only been performed in adults.
Raziskave o interakcijah so izvedli samo pri odraslih.
Interaction studies have only been performed in adults.
Študije medsebojnega delovanja z drugimi zdravili so opravili samo pri odraslih.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin.
Študije medsebojnega delovanja so pokazale, da pioglitazon nima pomembnih učinkov niti na farmakokinetiko niti na farmakodinamiko digoksina, varfarina, fenprokumona ali metformina.
Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below.
Študije medsebojnega delovanja so bile opravljene z 10 in/ali 20 mg tadalafila, kot je prikazano spodaj.
Interaction studies with exenatide have only been performed in adults.
Študije medsebojnega delovanja z eksenatidom so izvedli le pri odraslih.
Interaction studies with these agents have only been performed in adults.
Študije medsebojnega delovanja s tema učinkovinama so izvedli le pri odraslih.
interaction studies.
interakcij zdravil.
Interaction table
Preglednica medsebojnih delovanj z drugimi zdravili
Interaction table
Preglednica medsebojnih delovanj zdravil
interaction with bone void fillers
interakciji s polnili za luknje v kosteh, enkratni uporabi zdravila;
Interaction with coumarin-derived anticoagulants including warfarin leading to increased International Normalized Ratio (INR), and bleeding events, which in some cases were fatal, have been reported in patients receiving Tarceva.
Pri bolnikih, ki so prejemali zdravilo Tarceva, so poročali o medsebojnem delovanju s kumarinskimi antikoagulanti, vključno z varfarinom, ki je vodilo do povišanja internacionalnega normaliziranega razmerja (INR) in krvavitev, ki so se v nekaterih primerih končale s smrtnim izidom.
Interaction with didanosine: Co-administration of Atripla and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Interakcije z didanozinom: Sočasno dajanje zdravila Atripla in didanozina se ne priporoča, saj povzroči 40–60 % zvišanje sistemske izpostavljenosti didanozinu, kar lahko poveča tveganje neželenih reakcij, povezanih z didanozinom (glejte poglavje 4.5).
Interaction with didanosine: Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Medsebojno delovanje z didanozinom: Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina ni priporočljiva, saj povzroča povečanje sistemske izpostavljenosti didanozinu za 40–60%, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
Interaction with Grapefruit juice
Interakcija s sokom grenivke
Interaction with indinavir/ritonavir
Medsebojnega delovanja z
Interaction with indinavir/ritonavir
Medsebojnega delovanja z indinavirjem/ritonavirjem niso preučevali.
Interaction with indinavir/ritonavir not studied
Medsebojnega delovanja z
Interaction with indinavir/ritonavir not studied Morphine levels may be decreased due to induction of glucuronidation by coadministered ritonavir.
Medsebojnega delovanja z indinavirjem/ritonavirjem niso preučevali.
Interaction with inducers of both CYP3A4 and P-gp
Interakcije z zdravili, ki so induktorji tako CYP3A4 kot P-gp
Interaction with Invirase/ritonavir not
Medsebojno delovanje z drugimi
Interaction with Invirase/ritonavir not
Medsebojno delovanje z drugimi zdravili
Interaction with Invirase/ritonavir not
Medsebojno delovanje z zdravilom
Interaction with Invirase/ritonavir not
Medsebojno delovanje z zdravilom Invirase/ritonavirjem ni bilo proučevano.
Interaction with Invirase/ritonavir not
zdravilo kontraindicirano z
Interaction with Invirase/ritonavir not studied.
(sakvinavir/ritonavir)
Interaction with Invirase/ritonavir not studied.
povišanimi vrednostmi transaminaz
Interaction with Invirase/ritonavir not studied.
zdravila Invirase,
Interaction with moderate CYP3A4 inhibitors
Medsebojno delovanje z zmernimi zaviralci CYP3A4
Interaction with other medicaments and other forms of interaction
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interaction with other medicaments:
Interakcija z drugimi zdravili
Interaction with other medicinal product and other forms of interaction
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interaction with other medicinal products affecting haemostasis
Interakcije z drugimi zdravili, ki vplivajo na hemostazo
Interaction with other medicinal products and other forms of interaction
Interakcija z drugimi zdravili in druge oblike interakcij
Interaction with other medicinal products and other forms of interaction
Medsebojno de lovanje z drugimi zdravili in druge oblike interakcij
Interaction with other medicinal products and other forms of interaction
Medsebojno delovanje z drugimi zdravili in druge oblike intrerakcij
Interaction with other medicinal products and other forms of interaction
Medsebojno delovanje z drugimi zdravili in ostale oblike interakcij
Interaction with other medicinal products and other forms of interaction
Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Interaction with other medicinal products and other forms of interaction Interaction studies have only been performed in adults.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Raziskave interakcij so izvajali samo pri odraslih.
Interaction with other medicinal products and other forms of interaction Interaction studies have only been performed in adults.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Študije medsebojnega delovanja so izvedli le pri odraslih.
Interaction with other medicinal products and other forms of interaction Intravenous Anaesthetics:
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Intravenski anestetiki:
Interaction with other medicinal products and other forms of interaction:
Medsebojno delovanje z drugimi zdravili
Interaction with other medicinal products and other forms of interaction:
Medsebojno delovanje z drugimi zdravili:
Interaction with other medicinal products and other forms of interaction: For subcutaneous route:
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Za subkutano dajanje:
Interaction with other medicinal products and other forms of interaction: Inform your veterinary surgeon if your dog is using other medicines.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Obvestite svojega veterinarja, če vaš pes dobiva druga zdravila.
Interaction with other medicinal products and other forms of interaction: None known.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Niso znane.
Interaction with other products and other forms of interaction:
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: